Ipca Laboratories Limited · NSE:IPCALAB
Ipca Laboratories — Investor Presentation (September 2024)
63 slides from Ipca Laboratories's investor presentation, September 2024
Slide 1: Corporate Presentation September 2024
£ipca A dose of life Ipca Laborate Corporate Presentation September 2024
Slide 2: About Us
About Us a Q@©00€ Incorporation Consolidated Income Export to | >16,000 — 70+ —FY203-24 «104 Employees . Manica bs years | 37,830 crs | counties with : ms : ™ USS9500n oneste
Slide 3: Our Values
Our Values a wae Qualiti Safeti Integriti | Digniti _ Responsibilit’ Adhere to Ensure safety Comply with Value Facilitate good standards comes first : ethics & standards; people : business practices
Slide 4: Five Years' Highlights (Standalone)
Five Years’ Highlights XN 6,277.75 %5,925.81 ($757.82) %5,491.22 ($738.69) beeing (5737.38) 4,432.12 ($625.65) 3,570.05 2,983.09 een ($430.96) %2,484.21 1983. ($409.17) 2,288.37 ($333.94) _ eo ‘o——- —O -O —O— bl 2,717.19 2,508.13 2,643.42 ei 22,143.75 (5365.26) (5336.80) ($329.52) . a 652.46 9" 1,14
Slide 5: Five Years' Highlights (Consolidated)
Five Years’ Highlights Consolidated ( 27,829.81 ) 8000 (5945.17) %6,369.94 7000 5,490.83 5,896.36 ($794.06) /AB2. 791.78 6000 ($737.03) ae 24,715.71 5000 ($665.68) 3,391.06 %4090.77 4000 vee en ($422.72) ($493.82) 2,327.88 398.31 : 3000 2 3,739.04 ($328.61) : ($451.35) 2000 2,818.61 2,978.88 —O- i 2
Slide 6: Manufacturing Facilities
Slide 7: Manufacturing Facilities (Formulations)
Manufacturing Facilities (Formulations) Kandla Baddi? Dehradun Jorethang (B-lactum) (2 facilities) (2 facilities) (2 facilities) Ratlam , t t New Delhi * + B capital BD Corporate Office ¥ Ghaziabad" B® Formulations BW Biotech Overseas ae if 4 Mumbai Pithampur Piparia (Biotech) Pisgah Labs Mumbai Ath
Slide 8: Manufacturing Facilities (Formulations)
Athal (Dadra & Nagar Haveli) Ratlam (Madhya Pradesh) Kandla (Gujarat) Silvassa (Dadra & Nagar Haveli) Dehradun (Uttarakhand) Indore (SEZ) (Madhya Pradesh) Sikkim Tarapur, Palghar (Maharashtra) Tablets & Capsules Tablets, Liquids, Dry Syrup, Injectables & Ointments Betalactum-Tablets, Capsules & Dry
Slide 9: Manufacturing Facilities: Active Pharmaceutical Ingredients
RRS Manufacturing Facilities larmaceutical Ingredients eae ‘
Slide 10: Manufacturing Facilities (APIs)
Manufacturing Facilities (APIs) Onyx Scientific (Sunderland, UK) Baroda Dewas Nandesari New Delhi Ratlam Ranu | ; GB capital (R&D) : BD Corporate Office apis B® reo Overseas =——# ’ Hingni Mumbai Pithampur’ Mumbai Chh. Sambhajinagar + . (rap) Mahad vy » —_ (2Fadlties) + Pisgah Labs Ankleshwar — Tarap
Slide 11: Manufacturing Facilities (APIs)
Manufacturing Facilities (APIs) [ Location | Inspections / Approvals by Agencies of ] e@ Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDQM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO © Indore Madhya Pradesh) nig WHO @ Dewas (Madhya Pradesh) India © Ankleshwar(Gujart) =n Japan
Slide 12: Revenue Break-up
Reven we Break- -up
Slide 13: Revenue Break-up (Standalone 2023-24)
Revenue Break-up (Standalone 2023-24) Total Total Revenue Exports Domestic 2023-24 2023-24 2023-24 2023-24 43% 46% 54% | e e e Formulations: APIs Formulations e e e e APIs Formulations ; Export Domestic : APIs @ Formulations @ APIs B® Domestic @ Exports B® Formulations @ APIs @ Formulations @ APIs
Slide 14: Revenue Break-up (Standalone)
Revenue Break-up (Standalone) 2023-24 2022-23 Crs | Domestic | Exports | Total | Domestic | Exports | Total Growth | © Branded Formulations 3,097.16 526.70 3,623.86 2,760.71 504.79 3,265.50 q pen isiton/ - 1,248.62 «1,248.62 : 1,134.40 1,134.40 © Total Formulations 3,097.16 1,775.32 4,872.48 2,760.7
Slide 15: Financials
Slide 16: Standalone FY 2023-24
Standalone FY 2023-24 FY 2022-23 Zs US$ Mn | (Bers US$ Mn | % Growth @ Total Income 6,277.75 758 5,925.81 — e EBIDT 1,189.54 144 942.86 e EBIDT% 19.29% = 16.22% @ PBT* 955.52 115 750.49 e@ PBT% 15.5% = 12.91% @ PAT* 530.41 64 505.70 @ PAT% 8.60% = 8.70% # After forex gain of $21.84 Crs as against fo
Slide 17: Financials Standalone: Profitability
Financials Standalone CO Profitability | FY 2023-24 FY 2022-23 e PBIDT 19.29% @ point WB Pst WB PAT @ point WB Pst WB PAT
Slide 18: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 19: Financials Standalone: Net Profit
Financials Standalone FY 2023-24 FY 2022-23 @ Net Profit 4.9% 41.2%
Slide 20: Standalone Q1 FY25
Standalone Q1 FY25 Q1 FY24 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 1,581.25 190 1,529.50 — e EBIDT 348.44 42 284.28 e EBIDT% 22.25% - 19.13% @ PBT* 287.89 35 249.78 e@ PBT% 18.4% - 16.81% @ PAT* 204.13 24 166.58 @ PAT% 13.03% - 11.21% # After forex gain of €4.80Crs as against €13.45 Cr
Slide 21: Standalone Q2 FY25
Standalone Q2 FY25 Q2 FY24 Zs US$ Mn Zs US$ Mn | % Growth @ Total Income 1,827.94 218 1,698.80 e EBIDT 414.48 49 346.77 20% e EBIDT% 22.89% = 20.86% @ PBT 339.21 40 284.42 e@ PBT% 18.73% = 17.11% @ PAT* 244.12 29 162.13 @ PAT% 13.48% = 9.75% # After forex loss of €12.37 Crs as against forex gain of
Slide 22: Standalone H1 FY25
Standalone H1 FY25 H1 FY24 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 3,409.19 408 3,228.30 — e EBIDT 762.92 91 631.05 e EBIDT% 22.59% - 20.04% @ PBT* 627.10 75 534.20 e@ PBT% 18.57% - 16.96% @ PAT* 448.25 54 328.71 @ PAT% 13.27% - 10.44% # After forex loss of €7.57Crs as against forex ga
Slide 23: Consolidated FY 2023-24 vs FY 2022-23
FY 2023-24 FY 2022-23 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 7,829.81 945 6,369.94 e EBIDT 1,288.21 156 958.28 e EBIDT% 16.72% - 15.35% e@ PBT* 842.67 102 745.29 @ PBT% 10.94% - 11.94% e@ PAT* 547.35 66 471.32 @ PAT% 7.10% - 7.55% # After forex gain of €32.95 Crs as against forex loss o
Slide 24: Financials Consolidated: Business Characteristics
Financials Consolidated Business Characteristics FY 2023-24 FY 2022-23 Return on Capital Employed % (PBIT / Capital Employed) 16.30% 15.21% Return on Net Worth % (PAT / Net Worth) 11.47% 10.71% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.12 2.92 Capital Employed Turnover Ratio (To
Slide 25: Financials Consolidated: Net Profit
Financials Consolidated FY 2023-24 FY 2022-23 @ Net Profit 9.2% 46.7%
Slide 26: Consolidated Q1 FY25
Q1FY25 Q1 FY 24 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 2,113.24 253 1,630.06 e EBIDT 387.49 46 294.33 e EBIDT% 18.52% - 18.57% e@ PBT* 290.39 35 251.82 @ PBT% 13.88% - 15.89% @ PAT* 192.24 2 162.82 @ PAT% 9.19% - 10.27% # After forex gain of €5.23 Crs as against €13.49 Crs for previous
Slide 27: Consolidated Q2 FY25
Q2 FY 25 Q2 FY 24 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 2,381.16 284 2,072.50 e EBIDT 449,83 54 358.77 e EBIDT% 19.10% - 17.64% e@ PBT* 344.83 35 225.36 @ PBT% 14.64% - 11.08% @ PAT* 229.48 27 145.06 @ PAT% 9.74% - 7.13% # After forex loss of $8.35 Crs as against forex gain of €1.79 Cr
Slide 28: Consolidated H1 FY25
H1 FY 25 H1 FY 24 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 4,494.40 537 3,702.56 e EBIDT 837.32 100 653.10 e EBIDT% 18.83% - 18.05% e@ PBT* 635.22 76 477.18 @ PBT% 14.28% - 13.18% e@ PAT* 421.72 50 307.88 @ PAT% 9.48% - 8.51% # After forex loss of $3.12 Crs. as against forex gain of €15.2
Slide 29: Contribution of Therapeutic Groups
Financials Standalone Contribution of Therapeutic Groups a Therapeutic Segment — 2023-24 Domestic 2022-23 © Cardiovasculars& Anti-Diabetics © Anti-Malarials © Neuro Psychiatry e 3% 3% © Dermatology e 6% 6% © Neutraceuticals e % 1% Le es Export 2023-24 2022-23 © Cardiovasculars & Anti-Diabetics © Ant
Slide 30: Branded Formulations
Branded| Formulations
Slide 31: Branded Formulations: Domestic
Branded Formulations a Domestic . 21 Market leaders in All India Rank IQVIA Therapy Focused Over 4000 Rheumatoid Arthritis 16" (MAT Sept’24) Marketing Divisions Wholesalers & Anti-malarials Gy @ 24 Depots & Field Strength 6 brands among ‘1 C&F agent (PSR / BA)-6577 top 300 brands (Zerodol-SP, Zerodo
Slide 32: Branded Formulations Domestic Sales
Branded Formulations Domestic 3,097.16 ($374.Mn) 2,760.71 3000 2,508.27 ($344 Mn) ($337 Mn) 2500 1,981.67 2000 ($266 Mn) 1500 1000 500 —O- 2023-24 0 T T T 2020-21 L 2020-21 2021-22 2022-23 2023-24 ) pe Figures in Crores. Sales
Slide 33: Branded Formulations: Future Growth Drivers
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS. rail +e Strong brand building with focused promotion. +—® In-licensing / out-licensing to build business in the promoted therapy. Portfolio optimisation, strategies t
Slide 34: International
\ Intern ational
Slide 35: International Business
International Business a Registrations in 59 countries © Recognised _A Field-force to promote brands © Five Star Export gu in more than House 30 countries Products of the company 43% sales & Marketing offices in are now exported to over From exports By 12 countries 100 countries across the globe
Slide 36: International Business Sales
International Business (— > 3000 %2,717.19 2,643.42 %2,707.70 ($365 Nin) we (8330 Ma) ($327 Mn) 2500 2000 1500 1000 500 —O- 2023-24 0 T T T 1 2020-21 L 2020-21 2021-22 2022-23 2023-24 ) O- mun Figures in Crores. Sales 36
Slide 37: Continent-wise Exports 2023-24
International Business a Continent-wise Exports 2023-24 (%Crs) Continent Formulations APIs | Total | % Contribution © Europe 468.73 315.26 783.99 29% © Africa 477.76 42.69 520.45 19% © Americas 184.88 255.49 440.37 16% @ Asia 134.18 267.10 401.28 15% e dls 206.76 45.89 252.65 9% © Australasia 303.01
Slide 38: International Formulations
Slide 39: International Formulations Sales
International Formulations 21,597.19 ~ %1,639.19 21,775.32 ($214 Mn) 204 Mi 1,486.74 Cony ($200 Mn) —O- 2023-24 XX T T 1 2020-21 2021-22 2022-23 2023-24 2021-22 yw, 2022-23 Figures in Crores. Sales
Slide 40: International: Branded Formulations
Intern ational
Slide 41: International Branded Formulations Sales
International Branded Formulations (— 526.70 > 530 504.79 ($64 Mn) 510 ($63 Mn) 490 470 450 %415. 430 £403.42 cae ($54 Mn) 410 390 370 350 —O— 2023-24 330 T T T 1 2020-21 L 2020-21 2021-22 2022-23 2023-24 pa Figures in Crores. Sales 4]
Slide 42: International Branded Formulations: Future Growth Drivers
International Branded Formulations Future Growth _ Thrust on brand building in Pain, CVS, CNS, Anti-infective Drivers and Anti-malarial segments. ral '—® Geographical expansion in covered countries through additional field force. '—® Expansion in business lines - Institutions and Distributors. Intro
Slide 43: International: Generics / Institution / Tender
@ eo ae tional NS nstitution / Tender so Ane SS 5
Slide 44: International Generics / Institution / Tender
International Generics / Institution / Tender >) Count Products Products Under 1400 e1403.77 Tues ountry Registered Registration 160M 1,134.40 ited Ki 1200 ($160 Mn) ome (141 Mn) United Kingdom 57 4 ($144 Mn) / Europe 1000 Australia / New Zealand @ é 800 South Africa 53 10 cou United States / 47 4 4
Slide 45: International Generics: Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. al Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Futur
Slide 46: International: APIs
internat ational
Slide 47: International APIs Sales
International ~ APIs 1,120.00 1200 (6151 Mn) %1,021.39 %1,004.23 ($137 Mn) ($125 Mn) £932.38 1000 (5113 Mn) 800 600 400 200 —O- 2023-24 0 T T T 2020-21 L 2020-21 2021-22 2022-23 2023-24 pa Figures in Crores. Sales
Slide 48: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API US-FDA Canada- wHo | /Pa% | Australia| EQDM 1 1 Alendronate Sodium () cs - 7) - i} 2 2 Allopurinol (7) @ = = CEP @ 3 3 Amlodipine Besylate () - - - @ 4 Amlodipine Besylate (AK4 Process) - - - = ° G@ 4 5 Amodiaquine HCI = S @ - - - 5 6 A
Slide 49: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 11 12 12 13 13 14 14 15 15 16 16 7 18 17 19 18 20 21 19 22 Name of the API Benzarone Benzbromarone Bisoprolol Fumarate Bupropion Hydrochloride Carvedilol Celecoxib Cetrizine Hydrochloride (CZ Process) Cetrizine Hydrochloride (CZ5 / CZ6 Process) Chloroquine Phosphate Chlort
Slide 50: APIs - Drug Master Files
International APIs - Drug Master Files 31 Famotidine (FM3 Process) 2 - - i] - 27 32 Fenofibrate = 2 - - - 28 33 Fluconazole > 2 - - - AA DME | Name of the API US-FDA Canada- wHo | /Pa% | Australia| EQDM 20 23 Citalopram HBR - = = o - @ 21 24 __Dihydroartemesinin - = Gg - - - 22 25 Donepezil Hydrochl
Slide 51: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Sept’24 (Based on DMFs Sr. No.) API | DMF Canada- Japan- Sr. No.| Sr. No. Name of the API US-FDA HPEB WHO PMDA Australia EQDM | 0 35 Furosemide @ — : i) CEP @ 36 Furosemide (Veterinary) a re 38 Hydrochlorothiazide (Process |) 32. 39 ~—_-H
Slide 52: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API usFoa | Canada yg | JPan justralia | EQDM 37 45 Lamotrigine - = = 2 - () 46 Losartan Potassium (LB3 Process) (7) 2 2 - - . 38 47 Losartan Potassium (LB4 Process) - - 2 2 - (7) 48 Losartan Potassium (LB7 Process) = g - - = i) 39 49 — Lum
Slide 53: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Sept’24 (Based on DMFs Sr. No.) API | DMF 7 Canada- Japan- si A F | Name ofthe AP | US-FDA i | wHo | /apan- EQDM | 56 Methylphenidate HCI ee 58 Metoclopramide HCI 59 Metoclopramide HCl (M Process) ce 61 Metoprolol Tartrate 62 Metoprolol T
Slide 54: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 53 67 54 68 55 69 56 70 57 71 58 72 59 73 60 74 61 75 62 76 63 77 Name of the API Ondansetron Base Ondansetron Hydrochloride Paroxetine HCI Piperaquine Phosphate Primaquine Phosphate Probenecid Proguanil Hydrochloride Promethazine Hydrochloride Propranolol HCI Pyrantel Emb
Slide 55: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 64 78 79 65 80 66 81 67 82 68 83 84 69 85 70 86 87 71 88 Name of the API Pyrimethamine Quetiapine Fumarate Quetiapine Fumarate (QT5 Process) Ractopamine HCI Risendronate Sodium Hemi-Pentahydarate Risperidone Telmisartan Telmisartan (WT3A Process) Torsemide Tramadol Hydroch
Slide 56: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Sept’24 (Based on DMFs Sr. No.) ‘sto iA Name of the API | US-FDA | Canada | WHO | Japan: | Australia | EQDM | 2 89 Trazodone Hydrochloride - - = o - ) 73 90 _Triamterene go - - - @ 91 Trimethoprim : : : @ CEP (7) 74 92 Trimethoprim (T Pro
Slide 57: International APIs: Future Growth Drivers
International APIs -—® Consolidate API business of Sartans across the globe. Future Growth Drivers ‘—© Long term strategic tie-ups with major South American / European formulators. Leverage the customer base of more than 1000 customers spread across 90 _A countries is well laid down platform to intr
Slide 58: Research & Development
AS Resear rh& Development
Slide 59: Research & Development Spending
Research & Development APls & Formulations ( >) Year | TCs | sta saes | 180 156.49 161.50 4.50% \ 2.64% 160 u 46.46 271% 4.00% 2019-20 101.04 2.35% %126.67 140 545% 3.50% 2020-21 126.67 2.49% 120 Mis 200% 2021-22 141.46 2.63% 100 2.50% 80 2.00% 2022-23 156.49 271% 60 1.50% 2023-24 161.50 2.64% 40 1.
Slide 60: Research & Development: APIs & Formulations
Research & Development APls & Formulations -—® Current scientist manpower of 625+. Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 248 patent applications filed. Biotech / fermentation
Slide 61: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing -—® Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable of in-house development from “Clone to Commercialization” Single-use CGMP Bio-manufacturing Facility (DS+DP+QC) is being established and to be ready b
Slide 62: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines 7 Molecules: Anti-cancer , Anti-inflammatory and OpthalmicmAbs Stage of Development [ Molecules e 7 Monoclonal antibodies (mAbs) and One Non-mAb MAA/Launch Biosimilar at various stages of the development UK/HC/IN/EU © Target markets India, UK, HC, EU, ROW en 7 ee {___._..
Slide 63: Thank You
Ipca Laboratories — Investor Presentation (September 2024) on 6ix